Skip to content

GENEREX BIOTECHNOLOGY CORP: comprehensive income or loss

Comprehensive income or loss for GENEREX BIOTECHNOLOGY CORP. Inspect selected reporting periods, original units and SEC filing links; download the financial history.

All GENEREX BIOTECHNOLOGY CORP financial histories

What this measure means

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Exact concept: us-gaap:ComprehensiveIncomeNetOfTax. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 1996-07-31 to 2015-07-31. The SEC response was captured on 2026-09-22.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Comprehensive income or loss in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2014-08-012015-07-31-2,156,695USD2015-10-0910-K · 0001607062-15-000445
2013-08-012014-07-315,554USD2015-10-0910-K · 0001607062-15-000445
2012-08-012013-07-31-6,893,018USD2013-10-1110-K · 0001554795-13-000602
2011-08-012012-07-31-9,582,238USD2013-10-1110-K · 0001554795-13-000602
2010-08-012011-07-31-21,590,475USD2013-10-1110-K · 0001554795-13-000602
2010-07-312011-07-31-21,590,475USD2012-10-1510-K · 0001144204-12-056138
2009-08-012010-07-31-25,147,344USD2013-10-1110-K · 0001554795-13-000602
2009-07-312010-07-31-25,147,344USD2012-10-1510-K · 0001144204-12-056138
2008-08-012009-07-31-46,075,136USD2013-10-1110-K · 0001554795-13-000602
2008-07-312009-07-31-46,075,136USD2012-10-1510-K · 0001144204-12-056138
2007-08-012008-07-31-36,196,303USD2013-10-1110-K · 0001554795-13-000602
2006-08-012007-07-31-23,377,232USD2013-10-1110-K · 0001554795-13-000602
2006-07-312007-07-31-23,377,232USD2012-10-1510-K · 0001144204-12-056138
2005-08-012006-07-31-67,781,972USD2013-10-1110-K · 0001554795-13-000602
2005-07-312006-07-31-67,781,972USD2012-10-1510-K · 0001144204-12-056138
2004-08-012005-07-31-23,729,257USD2013-10-1110-K · 0001554795-13-000602
2004-07-312005-07-31-23,729,257USD2012-10-1510-K · 0001144204-12-056138
2003-08-012004-07-31-18,154,990USD2013-10-1110-K · 0001554795-13-000602
2002-08-012003-07-31-12,854,934USD2013-10-1110-K · 0001554795-13-000602
2002-07-312003-07-31-12,854,934USD2012-10-1510-K · 0001144204-12-056138
2001-08-012002-07-31-13,764,219USD2013-10-1110-K · 0001554795-13-000602
2001-07-312002-07-31-13,764,219USD2012-10-1510-K · 0001144204-12-056138
2000-08-012001-07-31-27,178,551USD2013-10-1110-K · 0001554795-13-000602
2000-07-312001-07-31-27,178,551USD2012-10-1510-K · 0001144204-12-056138
1999-08-012000-07-31-8,808,533USD2013-10-1110-K · 0001554795-13-000602
1998-08-011999-07-31-6,238,209USD2013-10-1110-K · 0001554795-13-000602
1998-07-311999-07-31-6,238,209USD2012-10-1510-K · 0001144204-12-056138
1997-08-011998-07-31-4,862,563USD2013-10-1110-K · 0001554795-13-000602
1997-07-311998-07-31-4,862,563USD2012-10-1510-K · 0001144204-12-056138
1996-08-011997-07-31-1,375,481USD2013-10-1110-K · 0001554795-13-000602
1996-07-311997-07-31-1,375,481USD2012-10-1510-K · 0001144204-12-056138

Related GENEREX BIOTECHNOLOGY CORP histories

Inspect the source

Entity
GENEREX BIOTECHNOLOGY CORP / CIK 0001059784
Captured
SEC response SHA-256
a8779b8c3aa8286320834b30d50af09999238cecacb9e7883d21e11477763a4d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001059784.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))